Scientists who worked on the targeted leukemia drugs Gleevec and Sprycel may be in line for the Nobel Prize this year, a prize-prediction expert says. The drugs, sold by Novartis ($NVS) and Bristol-Myers Squibb ($BMY) respectively, represent "a fundamental discovery in medicine...with a fantastic result which is often referred to in terms like 'magic bullet'," analyst David Pendlebury tells Reuters. "It has really given a new paradigm for the treatment of cancer." Report